# CHRONIC INTERSTITIAL (RESTRICTIVE, INFILTRATIVE) LUNG DISEASES

MARAM ABDALJALEEL, MD.

DERMATOPATHOLOGIST

UNIVERSITY OF JORDAN, SCHOOL OF MEDICINE

### **SLICA:**

- naturally occurring mineral.
- accounts for 59% of the earth's crust.
- two types : crystalline silica (toxic) and amorphous.
- Several processes release silica into the air such as:

crushing, grinding, and blasting.



### **SILICOSIS**

The most prevalent chronic occupational disease in the world

Inhalation of crystalline silica mostly in occupational settings

quartz is most implicated in silicosis

Amorphus silica is less pathogenic

 Workers in sandblasting and hard-rock mining are at high risk.

### **PATHOGENESIS**

 After inhalation, the particles interact with epithelial cells and macrophages.

 Activating the inflammasome and the release of inflammatory mediators by pulmonary macrophages

• IL-1, TNF, fibronectin, lipid mediators, oxygen-derived free radicals, and fibrogenic cytokines.


 When mixed with other minerals, the fibrogenic effect of quartz is reduced.

 This fortuitous situation is commonplace, as quartz in the workplace is rarely pure.

### **MORPHOLOGY, SILICOTIC NODULES:**

### Macroscopically:

- early stages are tiny, barely palpable, discrete, pale-to-black (if coal dust is present) nodules
- Upper zones of the lungs




- Microscopically:
- Silicotic nodules:
  - Concentrically arranged hyalinized collagen fibers surrounding amorphous center.
  - With "whorled" collagen fibers
- Polarized microscopy reveals weakly birefringent silica


 Nodules may coalesce into hard, collagenous scars, with eventual progression to PMF


- Fibrotic lesions also may occur in hilar lymph nodes and pleura.
- The greater degree of exposure to silica and an increasing length of exposure → amount of silicotic nodule formation and the degree of restrictive lung disease.

### **SILICOTIC NODULE**



# SEVERAL COALESCENT COLLAGENOUS SILICOTIC NODULES





Silica cystals

### **CLINICAL FEATURES:**

 Asymptomatic: detected as fine nodularity in the upper zones of the lung on routine chest radiographs

 Most patients do not develop shortness of breath until late in the course.

- after PMF: Shortness of breath, pulmonary hypertension and corpulmonale
- The disease may continue to worsen even if the patient is no longer exposed.

 Silicosis is slow to kill, but impaired pulmonary function may severely limit activity

#### The onset of silicosis can be:

- slow and insidious (10 to 30 years after exposure; most common),
- accelerated (within 10 years of exposure)
- rapid (in <u>weeks or months</u> after intense exposure to fine dust high in silica; rare).

- Silicosis → increased susceptibility to tuberculosis.
  - crystalline silica inhibits the ability of pulmonary macrophages to kill phagocytosed mycobacteria.
- silica and lung cancer:
  - Patients with silicosis have double the risk for developing lung cancer.

### ASBESTOSIS AND ASBESTOS-RELATED DISEASES




### **ASBESTOS**


 Family of crystalline hydrated silicates with a fibrous geometry.

#### **ASSOCIATED WITH:**

- (1) parenchymal interstitial fibrosis (asbestosis);
- (2) localized fibrous plaques or, rarely, diffuse pleural fibrosis.
- (3) pleural effusions
- (4) Lung carcinomas
- (5) malignant pleural and peritoneal mesotheliomas
- (6) laryngeal carcinoma



Pleural Plaques suggest asbestos exposure and do not cause symptoms



Malignant Pleural Mesothelioma: Rare cancer of the lung lining

### ASBESTOSIS: IS SCARRING OF THE LUNG CAUSED BY ASBESTOS EXPOSURE

### **PATHOGENESIS:**


- once phagocytosed by macrophages → asbestos fibers activate
  the inflammasome and damage phagolysosomal membranes →
  release of proinflammatory factors and fibrogenic mediators →
- 1. cellular and fibrotic lung reactions
- 2. tumor initiator and a promoter
  - mediated by the oncogenic effects of reactive free radicals generated by asbestos fibers in the distal lung near the mesothelial lining


#### Asbestos and tobacco:

- The adsorption of carcinogens in tobacco smoke onto asbestos fibers results in remarkable synergy between tobacco smoking and the development of lung carcinoma in asbestos workers → Smoking enhances the effect of asbestos by interfering with the mucociliary clearance of fibers.
- asbestos workers → fivefold increase of lung carcinoma with asbestos exposure alone
- Asbestos exposure and smoking together
- →a **55-fold increase** in the risk.





### **MORPHOLOGY**







### Asbestos body with beading and knobbed ends







dense laminated layers of collagen (pink)



### **MORPHOLOGY**

 Diffuse pulmonary interstitial fibrosis indistinguishable from UIP.

#### Asbestos bodies:

- golden brown, fusiform or beaded rods with a translucent center.
- Formed of asbestos fibers coated with an iron-containing proteinaceous material

Begins in the lower lobes and subpleurally

#### Pleural plaques:

- the most common manifestation of asbestos exposure
- well-circumscribed plaques of dense collagen containing calcium
- anterior and posterolateral aspects of the parietal pleura and over the domes of the diaphragm

### **CLINICAL FEATURES:**

- Progressively worsening dyspnea at least after 10 years after first exposure. (typically, after 20-30 years after exposure).
- Dyspnea is the first manifestation (by exertion, but later at rest).
- cough and production of sputum (due to smoking mainly).

• **static or progress** to honeycomb lung, congestive heart failure, cor pulmonale, and death.

Pleural plaques are usually asymptomatic

### **OUTCOMES:**

 The risk for developing lung carcinoma is increased 5-fold for asbestos workers

 the relative risk for mesothelioma is more than 1000 times greater than the risk for lung cancer

 Concomitant cigarette smoking increases the risk for lung carcinoma but not for mesothelioma.

 Lung or pleural cancer associated with asbestos exposure carries a poor prognosis.

### **PULMONARY EOSINOPHILIA**

### **PULMONARY EOSINOPHILIA**

 number of disorders of immunologic origin, characterized by pulmonary infiltrates rich in eosinophils

# SMOKING-RELATED INTERSTITIAL DISEASES



# SMOKING-RELATED INTERSTITIAL DISEASES


- Desquamative interstitial pneumonia (DIP)
- respiratory bronchiolitis- Associated interstitial lung disease

### **DESQUAMATIVE INTERSTITIAL PNEUMONIA (DIP)**

 The most striking histologic feature of DIP is the accumulation of large numbers of macrophages containing dusty-brown pigment (smoker's macrophages) in the air spaces

 Sparse inflammation in alveolar septa (lymphocytes, plasma cells and eosinophils)

+/- mild Interstitial fibrosis +/- emphysema



#### **CLINCAL PRESENTATION AND OUTCOME:**

- Male= females, 4th-5th decade, all are smokers
- Insidious onset of <u>dyspnea</u> and <u>dry cough</u> over weeks or months
- PFT→ mild restrictive abnormality
- good prognosis
- excellent response to <u>steroids and smoking cessation</u>, however, some patients progress despite therapy.

# RESPIRATORY BRONCHIOLITIS – ASSOCIATED INTERSTITIAL LUNG DISEASE

- common lesion in <u>smokers</u>
- Histology:
  - presence of <u>pigmented intraluminal macrophages</u> akin to those in DIP, but in a <u>"bronchiolocentric" distribution (first- and second-order respiratory bronchioles).</u>
  - Aggregates of smokers' macrophages: Respiratory bronchioles, alveolar ducts, and peribronchiolar spaces
  - Mild peribronchiolar fibrosis.
  - Centrilobular emphysema is common but not severe
  - <u>Desquamative interstitial pneumonia</u> is often found in different parts of the same lung.

## RESPIRATORY BRONCHIOLITIS – ASSOCIATED INTERSTITIAL LUNG DISEASE

- Symptoms are usually mild → gradual onset of dyspnea and cough in 4<sup>th</sup> to 5<sup>th</sup> decade smokers with average exposures of over 30 pack-years of cigarette smoking.
- Cessation of smoking usually results in improvement.

 The term respiratory bronchiolitis-associated interstitial lung disease is used for patients who develop significant pulmonary symptoms, abnormal pulmonary function, and imaging abnormalities.

# THANK YOU!